Strategies to Overcome Challenges in Commercializing Treatments for Rare Diseases
By Kelly Cockerill, Vice President, Marsha Pelletier, Director, Philippe De Gaiffier, Consultant, and Carrie Jones, Partner
Rare Disease Day serves as a reminder of the ongoing collaborative effort in the healthcare industry to bring valuable new treatments for the over 300MM global rare disease patients.
Despite the rapidly advancing science and established unmet need for patients, rare disease drug manufacturers face several unique challenges when commercializing new products.
Health Advances, as a strategic healthcare and life sciences consulting firm, helps rare disease drug developers make smart decisions that will best position their products for broad patient access.
In our 30 years of work across the rare disease industry, we’ve identified several key success factors:
Interested in some of these examples? Please reach out to us or follow our blog so you don’t miss our future deep dives on these topics above and many more. https://healthadvancesblog.com
Contact
Carrie Jones cjones@healthadvances.com, Partner leads Health Advances’ Rare and Orphan Disease Practice.
###
Related Insights
Article
Navigating the challenges of large, international Phase III breast cancer trials
Jul 29, 2025
Video
Ensure End to End and Vein to Vein Success for your Clinical Trial Supply Chain
Oct 14, 2022
Blog
Membership in Clinical Research Data Sharing Alliance enables Parexel to shape the future of clinical trial data
Sep 7, 2022
Article
Part Two: The Emergence of Chinese MedTech on the Global Stage
Sep 7, 2022
Blog
Including patients in DCT design
Sep 13, 2022
Podcast
Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit
Sep 19, 2022
Blog
Taking a Proactive, Preventive Approach to Data Privacy in Clinical Documentation
Sep 26, 2022
Playbook
The upward trend of FSP outsourcing
Sep 29, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Podcast
Get Recruited to Be a Clinical Research Associate: The Benefits of Parexel’s FSP Program
Oct 27, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Related Insights
Article
Navigating the challenges of large, international Phase III breast cancer trials
Jul 29, 2025
Video
Ensure End to End and Vein to Vein Success for your Clinical Trial Supply Chain
Oct 14, 2022
Blog
Membership in Clinical Research Data Sharing Alliance enables Parexel to shape the future of clinical trial data
Sep 7, 2022
Article
Part Two: The Emergence of Chinese MedTech on the Global Stage
Sep 7, 2022
Blog
Including patients in DCT design
Sep 13, 2022
Podcast
Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit
Sep 19, 2022
Blog
Taking a Proactive, Preventive Approach to Data Privacy in Clinical Documentation
Sep 26, 2022
Playbook
The upward trend of FSP outsourcing
Sep 29, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Podcast
Get Recruited to Be a Clinical Research Associate: The Benefits of Parexel’s FSP Program
Oct 27, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022